Progress on the second generation inhibitors of hepatitis C virus NS3/4A serine protease / 国际药学研究杂志

ABSTRACT

The progress of the second generation inhibitors of HCV NS3/4A serine protease, based on the modifications to the first generation ones (telaprevir, boceprevir, BILN-2061), is reviewed. The second generation inhibitors can significantly improve potency, pharmacokinetic profiles, and to some degree reduce the resistance induced by the first generation ones. The structure-activity relationships of these inhibitors are also discussed.